ProDeg™ ABL001 derivative, Target protein ligand (Protein Degrader) (CAT#: PRLG-013)
Please feel free to contact us for a quote and further discussion with our scientists.
Datasheets
| Specifications |
|---|
| Product Description |
ABL001 derivative is an allosteric BCR-ABL inhibitor that engages the myristoyl binding pocket of ABL1 kinase. Its distinct binding mode enables construction of bifunctional molecules that direct ABL1 toward proteasomal clearance. |
| Molecular Formula |
C22H20ClF2N5O4 |
| Molecular Weight (Da) |
491.9 |
| Chemical Name |
methyl 1-[5-[[4-[chloro(difluoro)methoxy]phenyl]carbamoyl]-3-(1H-pyrazol-5-yl)pyridin-2-yl]pyrrolidine-3-carboxylate |
| Chemical Structure |
 |
| Purity |
0.99 |
| Size |
5 mg |
| Physical State |
Powder |
| Storage |
The power can be stored at 4 °C for 2 years or at -20 °C for 3 years. |
| Target Information |
|---|
| Target Name |
ABL1 |
| Alternative Names |
ABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL, c-ABL1, p150, v-abl |
| Introduction |
ABL1 is a non-receptor tyrosine kinase containing an SH3 domain, an SH2 domain, and a C-terminal kinase domain. It localizes to both the cytoplasm and nucleus, where it regulates cell proliferation, cytoskeletal dynamics, and DNA damage responses. |
| Gene ID |
25 |
| UniProt ID |
P00519 |
| Related Disease |
Chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal stromal tumor |
Our services are For Research Use Only. We do not provide direct services for patients.
